<p>XTX Topco Ltd 在最近向證券交易委員會提交的文件中表示，在第二季度減少了對 TransMedics Group, Inc. (NASDAQ:TMDX - 免費報告) 的持股比例，降幅為 18.8%。該機構投資者在季度內出售了 3,644 股後，持有該公司 15,698 股股票。XTX Topco Ltd 在 TransMedics Group 的持股在最近的報告期末價值為 2,104,000 美元。</p>
<ul>
<li>中型股的奇蹟：三隻在五月超越銷售預期的股票</li>
</ul>
<p>其他大型投資者最近也對該公司的持倉進行了調整。Opal Wealth Advisors LLC 在第二季度購買了價值約 26,000 美元的 TransMedics Group 新股。Smartleaf Asset Management LLC 在第一季度將其在 TransMedics Group 的持股比例提高了 44.3%。Smartleaf Asset Management LLC 現在擁有 440 股該公司的股票，價值 30,000 美元，此前在上個季度又購買了 135 股。Quarry LP 在第一季度將其在 TransMedics Group 的持股比例提高了 88.5%。Quarry LP 現在擁有 592 股該公司的股票，價值 40,000 美元，此前在上個季度又購買了 278 股。Sound Income Strategies LLC 在第二季度購買了價值約 48,000 美元的 TransMedics Group 新股。最後，CWM LLC 在第一季度將其在 TransMedics Group 的持股比例提高了 20.1%。CWM LLC 現在擁有 925 股該公司的股票，價值 62,000 美元，此前在上個季度又購買了 155 股。99.67% 的股票由機構投資者持有。</p>
<p>獲取 <strong>TransMedics Group</strong> 的提醒：</p>
<h2>TransMedics Group 股票下跌 0.2%</h2>
<p>TMDX 股票在週四開盤價為 145.75 美元。該公司的市值為 49.8 億美元，市盈率為 59.01，貝塔值為 2.05。TransMedics Group, Inc. 的 12 個月最低價為 55.00 美元，最高價為 148.50 美元。該公司的 50 日簡單移動平均線為 121.71 美元，200 日簡單移動平均線為 121.82 美元。該公司的債務與股本比率為 1.43，流動比率為 7.69，速動比率為 7.13。</p>
<ul>
<li>2025 年表現優異的三隻醫療科技股票</li>
</ul>
<p>TransMedics Group (NASDAQ:TMDX - 獲取免費報告) 最近在 10 月 29 日（星期三）發佈了其財報。該公司報告季度每股收益為 0.66 美元，超出分析師共識預期的 0.37 美元，超出幅度為 0.29 美元。TransMedics Group 的股本回報率為 31.42%，淨利潤率為 16.20%。該公司季度收入為 1.4382 億美元，而共識預期為 1.4533 億美元。去年同期，該公司每股收益為 0.12 美元。與去年同期相比，該公司的收入增長了 32.2%。TransMedics Group 已設定其 2025 財年的每股收益指引。整體來看，股票研究分析師預測 TransMedics Group, Inc. 今年將發佈 1 美元的每股收益。</p>
<h2>分析師評級上調與下調</h2>
<p>幾家研究公司已對 TMDX 發佈了報告。摩根士丹利將 TransMedics Group 的股票目標價從 115.00 美元上調至 123.00 美元，並在 8 月 1 日的報告中給予該股 &#34;持平&#34; 的評級。Piper Sandler 將 TransMedics Group 的目標價從 145.00 美元下調至 140.00 美元，並在 10 月 30 日的研究報告中對該股給予 &#34;超配&#34; 的評級。Evercore ISI 於 9 月 16 日的研究報告中開始覆蓋 TransMedics Group 的股票，給予 &#34;跑贏大盤&#34; 的評級，目標價為 155.00 美元。Jefferies Financial Group 於 10 月 13 日的研究報告中開始覆蓋 TransMedics Group 的股票，給予 &#34;買入&#34; 的評級，目標價為 145.00 美元。最後，Stifel Nicolaus 於 9 月 4 日的研究報告中開始覆蓋 TransMedics Group 的股票，給予 &#34;持有&#34; 的評級，目標價為 115.00 美元。七位股票研究分析師對該股給予了買入評級，五位給予了持有評級。根據 MarketBeat.com 的數據，TransMedics Group 的平均評級為 &#34;適度買入&#34;，平均目標價為 131.80 美元。</p>
<ul>
<li>三隻交易者喜愛的高增長股票，投資者應關注</li>
</ul>
<p><strong>閲讀我們對 TMDX 的最新分析</strong></p>
<h2>內部人士買入與賣出</h2>
<p>在相關消息中，董事 Edward M. Basile 於 10 月 29 日（星期三）出售了 4,142 股 TransMedics Group 股票，交易價格為每股平均 130.45 美元，總價值為 540,323.90 美元。出售後，該董事持有 2,866 股該公司的股票，價值約 373,869.70 美元。此交易代表其持倉減少了 59.10%。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，內部人士 Anil P. Ranganath 於 11 月 25 日（星期二）出售了 3,000 股該公司的股票，交易價格為每股平均 145.22 美元，總交易額為 435,660.00 美元。交易完成後，該內部人士直接持有 13,955 股該公司的股票，價值約 2,026,545.10 美元。該交易代表其持倉減少了 17.69%。有關此交易的更多細節可在官方 SEC 披露中找到。7.00% 的股票由內部人士持有。</p>
<h2>TransMedics Group 簡介</h2>
<p>(免費報告)</p>
<p>TransMedics Group, Inc. 是一家商業階段的醫療技術公司，致力於為美國及國際上的終末期器官衰竭患者轉變器官移植治療。該公司提供器官護理系統 (OCS)，這是一種便攜式器官灌注、優化和監測系統，利用其專有和定製技術在人體外複製接收器官的近生理條件。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 TransMedics Group</li>
<li>股息捕捉策略：你需要知道的事項</li>
<li>特斯拉被稱為 “必買” 股票——原因在這裏</li>
<li>消費品股票解析</li>
<li>為什麼黃金如此鍾愛特朗普，正如特朗普鍾愛黃金</li>
<li>突破股票：它們是什麼以及如何識別它們</li>
<li>谷歌的 Gemini 3 使博通股價飆升：TPU 成為焦點</li>
</ul>
<p><strong>想看看其他對 TMDX 感興趣的對沖基金持有哪些股票？</strong> 訪問 HoldingsChannel.com，獲取 TransMedics Group, Inc.（NASDAQ:TMDX - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 TransMedics Group 嗎？</h2>
<p>在考慮 TransMedics Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 TransMedics Group 並不在名單上。</p>
<p>雖然 TransMedics Group 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TMDX

<p>XTX Topco Ltd 在第二季度減少了對 TransMedics Group 的持股 18.8%，出售了 3,644 股。該股票開盤價為 145.75 美元，市值為 49.8 億美元。分析師的評級意見不一，普遍持有適度買入的共識，平均目標價為 131.80 美元。TransMedics 報告了強勁的財報，盈利超出預期，每股收益為 0.66 美元，營收同比增長 32.2%</p>

<p>XTX Topco Ltd lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 18.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,698 shares of the company's stock after selling 3,644 shares during the quarter. XTX Topco Ltd's holdings in TransMedics Group were worth $2,104,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>XTX Topco Ltd 在最近向證券交易委員會提交的文件中表示，在第二季度減少了對 TransMedics Group, Inc. (NASDAQ:TMDX - 免費報告) 的持股比例，降幅為 18.8%。該機構投資者在季度內出售了 3,644 股後，持有該公司 15,698 股股票。XTX Topco Ltd 在 TransMedics Group 的持股在最近的報告期末價值為 2,104,000 美元。</p>
</div><ul>
<li>Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May</li>
</ul>
<div class="lb-trans"><ul>
<li>中型股的奇蹟：三隻在五月超越銷售預期的股票</li>
</ul>
</div><p>Other large investors have also recently made changes to their positions in the company. Opal Wealth Advisors LLC bought a new stake in TransMedics Group during the second quarter valued at about $26,000. Smartleaf Asset Management LLC lifted its position in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after buying an additional 135 shares during the last quarter. Quarry LP boosted its holdings in shares of TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after buying an additional 278 shares in the last quarter. Sound Income Strategies LLC purchased a new position in shares of TransMedics Group in the 2nd quarter worth approximately $48,000. Finally, CWM LLC raised its stake in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after acquiring an additional 155 shares in the last quarter. 99.67% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投資者最近也對該公司的持倉進行了調整。Opal Wealth Advisors LLC 在第二季度購買了價值約 26,000 美元的 TransMedics Group 新股。Smartleaf Asset Management LLC 在第一季度將其在 TransMedics Group 的持股比例提高了 44.3%。Smartleaf Asset Management LLC 現在擁有 440 股該公司的股票，價值 30,000 美元，此前在上個季度又購買了 135 股。Quarry LP 在第一季度將其在 TransMedics Group 的持股比例提高了 88.5%。Quarry LP 現在擁有 592 股該公司的股票，價值 40,000 美元，此前在上個季度又購買了 278 股。Sound Income Strategies LLC 在第二季度購買了價值約 48,000 美元的 TransMedics Group 新股。最後，CWM LLC 在第一季度將其在 TransMedics Group 的持股比例提高了 20.1%。CWM LLC 現在擁有 925 股該公司的股票，價值 62,000 美元，此前在上個季度又購買了 155 股。99.67% 的股票由機構投資者持有。</p>
</div><p>Get <strong>TransMedics Group</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>TransMedics Group</strong> 的提醒：</p>
</div><h2>TransMedics Group Stock Down 0.2%</h2>
<div class="lb-trans"><h2>TransMedics Group 股票下跌 0.2%</h2>
</div><p>TMDX stock opened at $145.75 on Thursday. The company has a market capitalization of $4.98 billion, a P/E ratio of 59.01 and a beta of 2.05. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $148.50. The firm's fifty day simple moving average is $121.71 and its 200-day simple moving average is $121.82. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13.</p>
<div class="lb-trans"><p>TMDX 股票在週四開盤價為 145.75 美元。該公司的市值為 49.8 億美元，市盈率為 59.01，貝塔值為 2.05。TransMedics Group, Inc. 的 12 個月最低價為 55.00 美元，最高價為 148.50 美元。該公司的 50 日簡單移動平均線為 121.71 美元，200 日簡單移動平均線為 121.82 美元。該公司的債務與股本比率為 1.43，流動比率為 7.69，速動比率為 7.13。</p>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表現優異的三隻醫療科技股票</li>
</ul>
</div><p>TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm had revenue of $143.82 million for the quarter, compared to the consensus estimate of $145.33 million. During the same quarter in the prior year, the business earned $0.12 earnings per share. The company's revenue was up 32.2% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.</p>
<div class="lb-trans"><p>TransMedics Group (NASDAQ:TMDX - 獲取免費報告) 最近在 10 月 29 日（星期三）發佈了其財報。該公司報告季度每股收益為 0.66 美元，超出分析師共識預期的 0.37 美元，超出幅度為 0.29 美元。TransMedics Group 的股本回報率為 31.42%，淨利潤率為 16.20%。該公司季度收入為 1.4382 億美元，而共識預期為 1.4533 億美元。去年同期，該公司每股收益為 0.12 美元。與去年同期相比，該公司的收入增長了 32.2%。TransMedics Group 已設定其 2025 財年的每股收益指引。整體來看，股票研究分析師預測 TransMedics Group, Inc. 今年將發佈 1 美元的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>Several research firms have issued reports on TMDX. Morgan Stanley lifted their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, August 1st. Piper Sandler dropped their price target on TransMedics Group from $145.00 to $140.00 and set an &#34;overweight&#34; rating on the stock in a research note on Thursday, October 30th. Evercore ISI began coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They issued an &#34;outperform&#34; rating and a $155.00 price objective for the company. Jefferies Financial Group began coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a &#34;buy&#34; rating and a $145.00 target price for the company. Finally, Stifel Nicolaus began coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They set a &#34;hold&#34; rating and a $115.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, TransMedics Group has an average rating of &#34;Moderate Buy&#34; and an average price target of $131.80.</p>
<div class="lb-trans"><p>幾家研究公司已對 TMDX 發佈了報告。摩根士丹利將 TransMedics Group 的股票目標價從 115.00 美元上調至 123.00 美元，並在 8 月 1 日的報告中給予該股 &#34;持平&#34; 的評級。Piper Sandler 將 TransMedics Group 的目標價從 145.00 美元下調至 140.00 美元，並在 10 月 30 日的研究報告中對該股給予 &#34;超配&#34; 的評級。Evercore ISI 於 9 月 16 日的研究報告中開始覆蓋 TransMedics Group 的股票，給予 &#34;跑贏大盤&#34; 的評級，目標價為 155.00 美元。Jefferies Financial Group 於 10 月 13 日的研究報告中開始覆蓋 TransMedics Group 的股票，給予 &#34;買入&#34; 的評級，目標價為 145.00 美元。最後，Stifel Nicolaus 於 9 月 4 日的研究報告中開始覆蓋 TransMedics Group 的股票，給予 &#34;持有&#34; 的評級，目標價為 115.00 美元。七位股票研究分析師對該股給予了買入評級，五位給予了持有評級。根據 MarketBeat.com 的數據，TransMedics Group 的平均評級為 &#34;適度買入&#34;，平均目標價為 131.80 美元。</p>
</div><ul>
<li>3 High-Growth Stocks Traders Love and Investors Should Watch</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻交易者喜愛的高增長股票，投資者應關注</li>
</ul>
</div><p><strong>Read Our Latest Analysis on TMDX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 TMDX 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買入與賣出</h2>
</div><p>In related news, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the sale, the director owned 2,866 shares of the company's stock, valued at approximately $373,869.70. This trade represents a 59.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of the business's stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider directly owned 13,955 shares of the company's stock, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Edward M. Basile 於 10 月 29 日（星期三）出售了 4,142 股 TransMedics Group 股票，交易價格為每股平均 130.45 美元，總價值為 540,323.90 美元。出售後，該董事持有 2,866 股該公司的股票，價值約 373,869.70 美元。此交易代表其持倉減少了 59.10%。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，內部人士 Anil P. Ranganath 於 11 月 25 日（星期二）出售了 3,000 股該公司的股票，交易價格為每股平均 145.22 美元，總交易額為 435,660.00 美元。交易完成後，該內部人士直接持有 13,955 股該公司的股票，價值約 2,026,545.10 美元。該交易代表其持倉減少了 17.69%。有關此交易的更多細節可在官方 SEC 披露中找到。7.00% 的股票由內部人士持有。</p>
</div><h2>TransMedics Group Profile</h2>
<div class="lb-trans"><h2>TransMedics Group 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.</p>
<div class="lb-trans"><p>TransMedics Group, Inc. 是一家商業階段的醫療技術公司，致力於為美國及國際上的終末期器官衰竭患者轉變器官移植治療。該公司提供器官護理系統 (OCS)，這是一種便攜式器官灌注、優化和監測系統，利用其專有和定製技術在人體外複製接收器官的近生理條件。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than TransMedics Group</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Tesla Just Got Called a “Must Own” Stock—Here’s Why</li>
<li>Consumer Staples Stocks, Explained</li>
<li>Why Gold Loves Trump as Much as Trump Loves Gold</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Google's Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 TransMedics Group</li>
<li>股息捕捉策略：你需要知道的事項</li>
<li>特斯拉被稱為 “必買” 股票——原因在這裏</li>
<li>消費品股票解析</li>
<li>為什麼黃金如此鍾愛特朗普，正如特朗普鍾愛黃金</li>
<li>突破股票：它們是什麼以及如何識別它們</li>
<li>谷歌的 Gemini 3 使博通股價飆升：TPU 成為焦點</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TMDX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 TMDX 感興趣的對沖基金持有哪些股票？</strong> 訪問 HoldingsChannel.com，獲取 TransMedics Group, Inc.（NASDAQ:TMDX - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TMDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TransMedics Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 TransMedics Group 嗎？</h2>
</div><p>Before you consider TransMedics Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 TransMedics Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 TransMedics Group 並不在名單上。</p>
</div><p>While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 TransMedics Group 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

XTX Topco Ltd 出售了 3,644 股 TransMedics Group, Inc. $TMDX